Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Wisner Baum is representing a plaintiff in a trial against Merck and other lawsuits are ... in Wisner Baum's suits against Merck over its HPV vaccine, which is to prevent cervical cancer.

However, Merck faced a setback when Barclays (LON:BARC) Capital Inc. lowered its price target to $142, citing a reset in revenue estimates for the company's China Gardasil business. The adjustment ...

However, Merck faced a setback when Barclays (LON:BARC) Capital Inc. lowered its price target to $142, citing a reset in revenue estimates for the company's China Gardasil business. The adjustment ...

Kennedy Jr., President Trump’s nominee to run the Department of Health and Human Services, is giving away the fees that he could earn from litigation over Merck’s HPV vaccine Gardasil — to ...